Literature DB >> 20378736

Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).

C M Hysek1, F X Vollenweider, M E Liechti.   

Abstract

BACKGROUND: MDMA (3,4-methylenedioxymethamphetamine, 'Ecstasy') produces tachycardia and hypertension and is rarely associated with cardiovascular and cerebrovascular complications. In clinical practice, beta-blockers are often withheld in patients with stimulant intoxication because they may increase hypertension and coronary artery vasospasm due to loss of beta(2)-mediated vasodilation and unopposed alpha-receptor activation. However, it is unknown whether beta-blockers affect the cardiovascular response to MDMA.
METHODS: The effects of the non-selective beta-blocker pindolol (20 mg) on the cardiovascular effects of MDMA (1.6 mg/kg) were investigated in a double-blind placebo-controlled crossover study in 16 healthy subjects.
RESULTS: Pindolol prevented MDMA-induced increases in heart rate. Peak values (mean+/-SD) for heart rate were 84+/-13 beats/min after MDMA vs 69+/-7 beats/min after pindolol-MDMA. In contrast, pindolol pretreatment had no effect on increases in mean arterial blood pressure (MAP) after MDMA. Peak MAP values were 115+/-11 mm Hg after MDMA vs 114+/-11 mm Hg after pindolol-MDMA. Pindolol did not change adverse effects of MDMA.
CONCLUSION: The results of this study indicate that beta-blockers may prevent increases in heart rate but not hypertensive and adverse effects of MDMA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378736     DOI: 10.1136/emj.2009.079905

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  19 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  The α- and β-Adrenergic Antagonist Controversy with Sympathomimetic Agents.

Authors:  Matthew L Banks; Travis J Worst; Daniel E Rusyniak; Jon E Sprague
Journal:  J Emerg Med       Date:  2015-08-12       Impact factor: 1.484

3.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation.

Authors:  Cédric M Hysek; Yasmin Schmid; Anna Rickli; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Matthew B Young; Seth D Norrholm; Lara M Khoury; Tanja Jovanovic; Sheila A M Rauch; Collin M Reiff; Boadie W Dunlop; Barbara O Rothbaum; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-07-24       Impact factor: 4.530

5.  Pharmacological mechanisms underlying the cardiovascular effects of the "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV).

Authors:  Charles W Schindler; Eric B Thorndike; Masaki Suzuki; Kenner C Rice; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2016-11-16       Impact factor: 8.739

Review 6.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

7.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 8.  Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension.

Authors:  Andrew King; Mirjana Dimovska; Luke Bisoski
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

9.  Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats.

Authors:  Samantha J McClenahan; Michael D Hambuchen; Christy M Simecka; Melinda G Gunnell; Michael D Berquist; S Michael Owens
Journal:  Drug Alcohol Depend       Date:  2019-01-04       Impact factor: 4.492

10.  Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.

Authors:  Anna M Becker; Friederike Holze; Tanja Grandinetti; Aaron Klaiber; Vanja E Toedtli; Karolina E Kolaczynska; Urs Duthaler; Nimmy Varghese; Anne Eckert; Edna Grünblatt; Matthias E Liechti
Journal:  Clin Pharmacol Ther       Date:  2021-11-22       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.